Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 62,522

Document Document Title
WO/2019/055729A1
Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating M...  
WO/2019/054944A1
The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use i...  
WO/2019/054766A1
Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in prevent...  
WO/2019/055808A1
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X...  
WO/2019/053090A1
The present disclosure provides a compound of formula (I): (I); or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treatin...  
WO/2019/055832A1
Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods...  
WO/2019/053015A1
Compounds of the formula (I) wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...  
WO/2019/054430A1
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...  
WO/2019/052519A1
Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumo...  
WO/2019/054451A1
Provided are type-I, type-III, type-V and type-VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthal en-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyri din-3-yl) urea which are useful as bulk pharmaceutica...  
WO/2019/055687A1
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class l/IIB HDAC inhibitor and an androgen. In a still ...  
WO/2019/055590A1
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therape...  
WO/2019/053016A1
Compounds of the formula (I) wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...  
WO/2019/054427A1
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...  
WO/2018/075598A8
Provided herein are synthetic methods for the preparation of EZH2 inhibitors.  
WO/2019/053634A1
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharma...  
WO/2019/052440A1
A deuterium atom-substituted indole formamide derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a deuterium atom-substituted indole formamide derivative represente...  
WO/2019/047978A1
Disclosed are a compound of formula (1) containing a fluorochloropyridine oxime ester structure and a preparation method therefor and the the use thereof, and a herbicide comprising the compound which has an excellent herbicidal activity.  
WO/2019/049061A1
The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) where...  
WO/2019/051469A1
The present invention relates to compounds capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds, and...  
WO/2019/051199A1
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...  
WO/2019/046944A1
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibit...  
WO/2019/049965A1
[Problem] The purpose of the present invention is to provide: an organic compound which serves as a material for organic EL elements having high efficiency and high durability, and which has excellent characteristics such as excellent el...  
WO/2019/047686A1
Provided are compounds of Formula (I), pharmaceutically acceptable salt thereof, compositions and methods to treat liver disease and NASH.  
WO/2019/047094A1
A compound of the formula (I) wherein Q is selected from the group consisting of -C(CH 3) 2and (II); R is selected from the group consisting of (III) and (IV); or a pharmaceutically acceptable salt thereof; compositions, methods to treat...  
WO/2019/051125A1
The present invention is directed to novel aminobenzimidazole derivatives. The present invention is also directed to methods of treating a histone deacetylase (HDAC)-associated disease or inhibiting the histone deacetylating activity of ...  
WO/2019/049049A1
The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The ...  
WO/2018/215178A3
The invention relates to novel neutral or cationic ligand-metal ion complexes formed by a metal ion selected from among the transition or post-transition metals, excluding lanthanide ions Ln3+, and a ligand having one of the formulae (IA...  
WO/2019/047909A1
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3', R4, R4', R5, R6, R7, R8, m, and n are as defined in ...  
WO/2019/050794A1
The present invention provides a compound of Formula (I) wherein X is selected from the group consisting of (CH2)2- and CH2-CH(CH3)-; Q is selected from the group consisting of C(CH3)2 and Formula (a); or a pharmaceutically acceptable sa...  
WO/2019/048353A1
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particu...  
WO/2019/049021A1
The present invention relates to triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. The invention also relates to...  
WO/2019/051265A1
Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension...  
WO/2019/042443A1
A compound having tyrosine protein kinase JAK3-degradation activity. The structural formula of the compound is as shown by formula I. The compound can be used for preparing drugs for treatment of JAK3-related diseases.  
WO/2019/046795A1
The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1, and A2 are as described generally and in classes and subclasses herein, and additionall...  
WO/2019/042444A1
Provided is a compound for inhibiting and degrading tyrosine protein kinase ALK. Specifically provided is a compound as represented by the following formula I, wherein the definition of each group is as stated in the description. The com...  
WO/2019/045035A1
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...  
WO/2019/043372A1
There are described compounds of formula (I) in which X, R1, R2 and n are each as herein defined; and their use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the hedgehog pathway, such...  
WO/2019/043373A1
There are described compounds of formula (I) in which R1, R2, R3,R4 and R5 are each as herein defined; and their use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the hedgehog pathway,...  
WO/2019/043208A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  
WO/2019/043407A1
There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists o...  
WO/2019/046778A1
Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the tre...  
WO/2019/045085A1
The present invention provides 1-(N,N-disubstituted carbamoyl) 4-(substituted sulfonyl)triazolin-5-one derivatives represented by general formula 1 and 4-(N,N-disubstituted carbamoyl) 1-(substituted sulfonyl)triazolin-5-one derivatives r...  
WO/2019/044940A1
The present invention addresses the problem of providing a novel compound which has an antagonistic activity against a retinoid-related orphan receptor γ and can exhibit a therapeutic or prophylactic effect on an autoimmune disease such...  
WO/2019/042187A1
Provided are an aminopyrimidine compound as shown in formula (I), a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotope variant, a hydrate or a solvate thereof, and a pharmaceutical composition comprising...  
WO/2019/046667A1
Disclosed herein are herbicidal compositions containing a herbicidally effective amount of (a) a pyridine carboxylic acid herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof, and (b) a phytoene desaturase (PDS) inhi...  
WO/2019/046239A1
The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.  
WO/2019/043214A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  
WO/2019/017857A3
The invention relates to synthesis of potential anticancer effective 4-(3-(2-arylidenhydrazine- 1-carbonyl)-5-(aryl)-1H-pyrazole-1-yl) benzensulfonamide compounds, enlightenment of their structures and their cytotoxic activities.  
WO/2019/043217A1
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstre...  

Matches 1 - 50 out of 62,522